Successful Approval of manufacturing and laboratory facilities by Saudi Food and Drug Authority
May 10, 2023
New site approval! We are happy to announce that our manufacturing and laboratory facilities for oral solids at AET Laboratories in Hyderabad (India) have been successfully registered by…
TIEFENBACHER GROUP IS COMMITTED TO BECOMING CLIMATE NEUTRAL
April 28, 2023
We are pleased to share that TIEFENBACHER GROUP is committed to becoming climate neutral by the end of 2025*. As a value-driven healthcare company, dedicated to improving the life of…
RENOVATING HEADQUARTERS IN HAMBURG
April 21, 2023
Did you know that Tiefenbacher Group is currently renovating its headquarters in Hamburg, Germany? We are excited to share the first results of the restructuring and are pleased to…
TIEFENBACHER GROUP AT DCAT 2023 – THANKS FOR MEETING US IN NEW YORK CITY!
March 27, 2023
DCAT week – one of the world´s most important pharma events – has just come to an end. It was four very successful and inspiring days for TIEFENBACHER GROUP in New York City.…
TIEFENBACHER GROUP wishes a happy and healthy Chinese New Year 2023!
January 22, 2023
We at TIEFENBACHER GROUP appreciate the diversity of our colleagues very much and are happy to celebrate their local traditions together. In the culture of our Chinese partners and…
TIEFENBACHER GROUP WISHES A HEALTHY NEW YEAR 2023
January 3, 2023
From all over the world, we wish you a happy and healthy New Year 2023! In order to serve more than 80 national markets in the best possible way for our partners, we are particularly…
Thanks for visiting us at CPhI 2022 in Frankfurt!
November 10, 2022
CPhI 2022, the world`s leading pharma event, has just come to an end. It was wonderful to meet our valued customers and partners in person again. Our experts enjoyed three very…
TIEFENBACHER GROUP opens new manufacturing site in Cyprus
October 28, 2022
Did you know that TIEFENBACHER GROUP heavily invests in its in-house production capacities? We are excited to announce that our new manufacturing site in Cyprus was ceremoniously…
TIEFENBACHER GROUP and OnDosis launch the innovative healthcare brand OYSTA®
October 25, 2022
TIEFENBACHER GROUP and OnDosis are thrilled to announce the launch of OYSTA®. The new healthcare brand represents the cooperation initiated in September 2020, including the co-development…
Meet TIEFENBACHER GROUP at CPhI in Frankfurt from 1-3 Nov and discover our latest ideas to make pharmaceuticals more affordable, more available, and better than before!
October 4, 2022
We are very excited to meet our valued customers and partners once again on CPhI 2022, the world´s leading pharma industry event! Explore our new booth representing Tiefenbacher Group as…
Environmentally friendly and health-promoting: TIEFENBACHER GROUP offers bike leasing to employees
August 18, 2022
From racing bikes to E-bikes: since this year all our employees at our Hamburg headquarters can choose from a broad range of company bikes to lease. A great opportunity for everyone to…
TIEFENBACHER GROUP becomes member of the Pharmaceutical Supply Chain Initiative (PSCI)
May 24, 2022
We at TIEFENBACHER GROUP are committed to promote sustainable and responsible business along the whole pharmaceutical supply chain. That’s why we are excited to become a member of PSCI – a…
TIEFENBACHER GROUP OPENS NEW SITE FOR HIGHLY POTENT DRUGS IN INDIA
May 5, 2022
TIEFENBACHER GROUP is excited to announce the ceremonious opening of our new highly potent drug laboratory in Hyderabad, India. The completion of the new building is the first step for…
WORLD HEALTH DAY @ TIEFENBACHER GROUP
April 7, 2022
Today we celebrate World Health Day. In times of a global pandemic and a cruel war in Europe, it is more important than ever that we all work together to create a healthier tomorrow. Since…
TIEFENBACHER GROUP AT DCAT 2022 – THANKS FOR MEETING US IN NEW YORK CITY!
March 29, 2022
One of the world´s most important pharma events – DCAT week in New York City – has just come to an end. It was four very successful and inspiring days for TIEFENBACHER GROUP…
TIEFENBACHER GROUP STANDS WITH UKRAINE
March 8, 2022
To us at TIEFENBACHER GROUP, it is unbearable to witness what is happening in Ukraine. We condemn the Russian state´s invasion as a brutal act of war against a neighbouring sovereign…
MEET TIEFENBACHER GROUP DURING DCAT WEEK IN NEW YORK CITY FROM 21-24th MARCH!
February 9, 2022
Reach out to TIEFENBACHER GROUP at DCAT in New York City from 21-24th March and discover our latest ideas to make pharmaceuticals more affordable, more available, and better than before!…
TIEFENBACHER GROUP WISHES A HAPPY AND HEALTHY NEW YEAR 2022 FROM ALL OVER THE WORLD!
January 4, 2022
We at TIEFENBACHER GROUP wish you a happy and healthy new year 2022 from all over the world! Please watch the short video for our new year greetings from our colleagues from our three…
Three successful days for TIEFENBACHER GROUP at CPhI 2021 – thanks for visiting us in Milano!
November 17, 2021
With over 1,300 exhibitors and more than 20,000 attendees the world`s leading pharma event CPhI has just come to an end. It was three very successful days for TIEFENBACHER GROUP…
At TIEFENBACHER GROUP giving back to society is important to us: New school building in India
October 25, 2021
As a value-driven healthcare company, dedicated to improve the life of patients worldwide, we believe that it´s our responsibility to care about the environment and society –…
Reach out to TIEFENBACHER GROUP at CPhI in Milan from 9-11th Nov and discover our latest ideas to make pharmaceuticals more affordable, more available and better than before!
October 6, 2021
“Nothing can replace meeting each other in person!” says Oliver Schrader, Managing Director of Tiefenbacher Group. After nearly two years of mainly digital work, we are very excited to be back on…
TIEFENBACHER API + INGREDIENTS SECURES THE SUPPLY OF CONTROLLED SUBSTANCES FOR CUSTOMERS AND PATIENTS
June 22, 2021
We at TIEFENBACHER API + INGREDIENTS, a part of TIEFENBACHER GROUP, assure patients have a better access to controlled substance active pharmaceutical ingredients (API) to meet the needs of many…
TIEFENBACHER API + INGREDIENTS offers Pitavastatine Calcium for novel therapies
May 11, 2021
We at TIEFENBACHER API + INGREDIENTS help to bridge the gap between drug development and market access by providing high purity of Pitavastatin Calcium (NK-104 hemicalcium, EU-DMF) to assure…
TIEFENBACHER API + INGREDIENTS starts to offer the first API based on green chemistry
April 15, 2021
We at TIEFENBACHER API + INGREDIENTS are committed to drive green chemistry in the pharmaceutical raw material industry. Enviero Progesterone is an Active Pharmaceutical Ingredient (API) and the…
TIEFENBACHER API + INGREDIENTS offer GMP certificated Natural Medicinal Cannabidiol (CBD) with highest purity profile in the market
March 1, 2021
We bring pharma-quality standards of cannabis API for the benefit of Patients in Europe. CBD, short for Cannabidiol, is a chemical compound from the Cannabis sativa plant. It has no psychotropic…
TIEFENBACHER API + INGREDIENTS secures the supply of critical drug for COVID-19 Patients: Dexmedetomidine Hydrochloride
February 23, 2021
We ensure hospitals have access to the medicines needed for patient care, including Dexmedetomidine HCL. TIEFENBACHER API + INGREDIENTS delivers long-term solutions that help deliver top quality…
New TIEFENBACHER API website – part of the TIEFENBACHER GROUP Brand Relaunch
December 15, 2020
“We are very thrilled to officially announce our new TIEFENBACHER API website, representing the raw material business of TIEFENBACHER GROUP, and aiming to expand our role as a high-quality…
Tiefenbacher Group and OnDosis enter a strategic partnership for game-changing integration of medicines and digital health
September 3, 2020
Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. This collaboration strengthens both companies’…